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Abstract
Background Though there are several classes of antidepressant drugs available on the pharmaceutical market, depression that 
affects globally over 320 million people is still undertreated. Scientists have made attempts to develop novel therapeutical 
strategies to maximize effectiveness of therapy and minimize undesired reactions. One of the ideas is use of either dual-action 
agents or combined administration of two substances that affect diverse neurotransmissions. Thus, we investigated whether 
the selected CB receptor ligands (oleamide, AM251, JWH133, and AM630) can have an impact on the activity of bupropion 
and moclobemide. Bupropion belongs to the dual acting drugs, whereas moclobemide is an inhibitor of monoamine oxidase.
Methods The mice forced swim test and the tail suspension test were applied in order to determine the potential antidepres-
sant-like activity, whereas the HPLC method was used in order to assess the brain concentrations of the tested antidepressants.
Results An intraperitoneal injection of sub-effective doses of oleamide (5 mg/kg), AM251 (0.25 mg/kg), and AM630 
(0.25 mg/kg) increased activity of bupropion (10 mg/kg) in both behavioural tests. Effects of moclobemide (1.5 mg/kg) were 
potentiated only by AM251. These results were not influenced by the hypo- or hyperlocomotion of animals.
Conclusion The outcomes of the present study revealed that particularly activation or inhibition of the  CB1 receptor func-
tion may augment the antidepressant activity of bupropion, whereas only inhibition of the  CB1 receptor function manages to 
increase activity of moclobemide. Most probably, an interplay between CB receptor ligands and bupropion or moclobemide 
takes place at the cellular level.
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Introduction
Though there are several classes of antidepressant drugs 
available on the pharmaceutical market, depression that 
affects globally over 320 million people is still under-
treated. Not only insufficient efficacy of drugs is responsi-
ble for such a situation, but also a high rate of remissions, 
side effects, and patient’s non-compliance. Epidemiologi-
cal data have estimated that even up to 40% and up to 60% 
of depressed patients do not respond to the introduced anti-
depressant therapy and do not achieve complete remission, 
respectively [1]. Moreover, up to 50–85% of them experi-
ence relapses of the disease. Another great disadvantage 
of the approved antidepressants is their delayed onset of 
action—usually one should wait at least 2 weeks since the 
beginning of therapy to observe an improvement of clinical 
symptoms. Delayed onset of pharmacological action plus 
occurrence of adverse effects may encourage a depressed 
patient to abandon their treatment [2]. Therefore, over the 
last few decades scientists have made attempts to develop 
novel antidepressant drugs and/or therapeutical strategies 
to maximize effectiveness of therapy and minimize unde-
sired reactions. Since the pathophysiology of depression is 
multifactoral, one of the ideas is use of either dual-action 
agents or combined administration of two substances that 
affect diverse neurotransmissions (i.e. serotoninergic, 
dopaminergic noradrenergic, melatoninergic signalling) 
[3, 4]. Moreover, current experimental pre-clinical and 
clinical treatments for depression focus on substances with 
novel mechanisms of action targeting different pathways 
implicated in the pathogenesis of depression, including 
the stress axis, neurogenesis, inflammatory processes, 
oxidative stress, and glutamatergic, opioid, cholinergic, 
or endocannabinoid neurotransmissions. New compounds 
are tested both as monotherapy and as enhancers of the 
conventional antidepressant drugs [5]. When designing 
the present experiments, we decided to concentrate on 
the second option. Knowing that cannabinoid (CB) recep-
tor ligands are able to potentiate the activity of common 
antidepressants, i.e. the tricyclic imipramine, selective 
serotonine reuptake inhibitor—escitalopram, and selec-
tive inhibitor of noradrenaline reuptake—reboxetine [6], 
we wanted to check whether they can also affect the effects 
of other antidepressant drugs that have a little bit differ-
ent biological targets, such as bupropion and moclobe-
mide. Bupropion belongs to the dual acting antidepressant 
agents, and it acts via inhibition of reuptake of dopamine 
and noradrenaline. Moclobemide is a representative of the 
reversible and selective inhibitors of monoamine oxidase. 
As CB receptor ligands, we selected substances with doc-
umented antidepressant-like potential, i.e. oleamide and 
AM251—an agonist and inverse agonist/antagonist of  CB1 
receptors, as well as JWH133 and AM630—an agonist 
and inverse agonist/antagonist of  CB2 receptors, respec-
tively. Though moclobemide seems to produce rapid and 
significant improvement in the quality of life of people 
with depression, it should not be used concomitantly with 
other drugs that enhance the serotoninergic neurotransmis-
sion due to the risk of the serotonergic overactivity (i.e. 
hyperthermia, confusion, hyperreflexia and myoclonus) 
[7]. On the other hand, bupropion, which is frequently 
prescribed as a component of a combined antidepressant 
therapy, may cause adverse reactions related to dopamine 
over-stimulation (including nausea, insomnia, agitation, 
dry mouth, weight loss, psychosis, and the lowered sei-
zure threshold) [8]. We assume that the combination of 
moclobemide or bupropion with substances modifying the 
endocannabinoid system may improve the clinical effect of 
these agents and/or improve their safety profile (as a result 
of dose reduction) [9]. In order to investigate the influ-
ence of CB receptor ligands on the activity of bupropion 
and moclobemide, we performed two worldly recognized 
behavioural tests that are widely used for evaluation of the 
antidepressant potential, i.e. the mouse forced swim test 
(FST) and the mouse tail suspension test (TST). Addi-
tionally, we performed the pharmacokinetic analysis to 
determine whether the CB receptor ligands affect concen-
trations of the tested antidepressants in the mouse brain.
Materials and methods
Animals
The presented experiments were carried out on adult male 
Albino Swiss mice weighing about 25–30 g. Animals were 
housed in standard cages (8 mice/cage) with free access to 
food and water. Rooms at the animal facility were environ-
mentally controlled, with temperature of 22–23 °C, relative 
humidity of 45–55%, and with 12-h light/dark cycle. 7–10 
subjects represented one experimental group. The research 
was planned and executed in agreement with Polish and 
European law related to studies on laboratory animals, and 
the applied procedures were approved by the Local Ethics 
Committee.
Drugs
All CB receptor ligands, i.e. oleamide (cis-9,10-octa-
decenoamide, 5  mg/kg, Tocris), AM251 (N-(piperidin-
1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-
1H-pyrazole-3-carboxamide, 0.25 mg/kg, Tocris), JWH133 
((6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-
6,6,9-trimethyl-6H-dibenzo[b,d]pyran, 0.25 mg/kg, Toc-
ris), and AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)
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ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone, 
0.25 mg/kg, Tocris), were suspended in Tween 80 solution 
(1%). Bupropion (10 mg/kg, Abcam) and moclobemide 
(1.5 mg/kg, Sigma-Aldrich) were dissolved in saline. Both 
CB receptor ligands and antidepressant drugs were given 
intraperitoneally (ip) 30 and 60 min before behavioural test-
ing, respectively. Mice from the control groups were injected 
with either 1% aqueous solution of Tween and/or saline. The 
pre-treatment schedules and the tested doses were chosen on 
the basis of the literature data [10] and our previous experi-
mental projects [6, 11, 12]. A standard volume of liquid 
dosage forms (i.e. 10 ml/kg) was used.
Forced swim test (FST)
The FST was carried out according to the same protocol 
which we had applied previously [13]. Duration of immobil-
ity, i.e. the time when mice stopped struggling and remained 
floating, performing only movements necessary to keep its 
head above the water level, was measured for the last 4 min 
of the 6-min experiment.
Tail suspension test (TST)
The TST was carried out according to the same protocol 
which we had applied previously [13]. Duration of immobil-
ity, i.e. the time when mice stopped struggling, performing 
only movements necessary to breathe, was measured for the 
last 4 min of the 6-min experiment.
Spontaneous locomotor activity
The spontaneous locomotor activity was recorded automati-
cally with use of the animal activity meter Opto-Varimex-4 
Auto-Track (Columbus Instruments, USA), according to the 
same protocol which we had applied previously [13]. A trav-
elled distance was measured for the last 4 min of the 6-min 
experiment, which corresponded with the testing period 
taken into account the FST and the TST.
Pharmacokinetic assays
The murine brain levels of bupropion and moclobemide 
were determined according to the same protocol which we 
had applied previously by a high-performance liquid chro-
matography (HPLC) method [11]. Animals were decapi-
tated 60 min after injection of bupropion or moclobemide 
(given with or without the respective ligand of CB recep-
tors). The tests were reproducible with low intra- and inter-
day variation. (Coefficient of variation was less than 10%.) 
The extraction efficiencies of the analysed drugs and the 
internal standard ranged from 66 to 97%. Concentrations 
of bupropion and moclobemide were given for wet brain 
tissue in ng/g.
Statistical analysis
Statistical analysis of the obtained results was performed 
by either two-way analysis of variance (ANOVA) with 
Bonferroni’s multiple comparisons test or t test. Two-way 
ANOVA was used for the FST, TST, and measurements of 
the spontaneous locomotor activity, whereas t test was used 
for the pharmacokinetic studies. The outcomes were given as 
the mean ± standard error of the mean (SEM). When p was 
lower than 0.05, between-group differences were considered 
as significant.
Results
Effects of a combined administration of the  CB1 
receptor ligands and bupropion in the FST 
and the TST
Neither oleamide (5 mg/kg) nor AM251 (0.25 mg/kg) or 
bupropion (10 mg/kg) when administered alone signifi-
cantly changed behaviour of mice in the FST or in the TST. 
By contrast, after exposure to respective combinations, i.e. 
oleamide–bupropion or AM251–bupropion, the tested ani-
mals were swimming for a longer period than their control 
counterparts and they struggled for a longer time in the TST 
(Fig. 1). Accordingly, two-way ANOVA demonstrated the 
following statistical data for the FST: (1) a significant oleam-
ide–bupropion interaction [F(1,36) = 10.22; p = 0.0029] with 
a significant effect of oleamide [F(1,36) = 15.29; p = 0.0004] 
and a significant effect of bupropion [F(1,36) = 23.33; 
p < 0.0001], (2) a significant AM251–bupropion interac-
tion [F(1,27) = 12.89; p = 0.0013] with a significant effect 
of AM251 [F(1,27) = 20.57; p = 0.0001] and a significant 
effect of bupropion [F(1,27) = 42.35; p < 0.0001], and for 
the TST: (1) a significant oleamide–bupropion interaction 
[F(1,36) = 4.73; p = 0.0366] with a significant effect of 
oleamide [F(1,36) = 5.91; p = 0.0205] and a significant effect 
of bupropion [F(1,36) = 25.11; p < 0.0001], (2) a significant 
AM251–bupropion interaction [F(1,28) = 46.42; p < 0.0001] 
with a significant effect of AM251 [F(1,28) = 24.71; 
p < 0.0001] and a significant effect of bupropion 
[F(1,28) = 86.07; p < 0.0001].
Effects of a combined administration of the  CB2 
receptor ligands and bupropion in the FST 
and the TST
As illustrated in Fig. 2, a single injection of JWH133 
(0.25 mg/kg), AM630 (0.25 mg/kg), or bupropion (10 mg/
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kg) did not influence the swimming pattern of mice sub-
jected to the FST. Similarly, such a treatment did not 
modify animals’ behaviour in the TST. Whereas concur-
rent administration of AM630 and bupropion produced 
an anti-immobility effect in both tests, the combined 
treatment with JWH133 and bupropion generally was 
not more potent than monotherapy. Statistical analysis 
revealed a significant drug–drug interaction for AM630 
and bupropion (1) in the FST: F(1,28) = 9.64; p = 0.0043, 
with a significant effect of both AM630 [F(1,28) = 20.11; 
p = 0.0001] and bupropion [F(1,28) = 5.54; p = 0.0259], 
and (2) in the TST: F(1,28) = 4.37; p = 0.0457, with 
a significant effect of both AM630 [F(1,28) = 5.37; 
p = 0.0280] and bupropion [F(1,28) = 26.91; p < 0.0001]. 
JWH133–bupropion interaction turned out to be non-sig-
nificant in the FST: F(1,28) = 0.06; p = 0.8160 and in the 
TST: F(1,27) = 1.53; p = 0.2262.
Effects of a combined administration of the  CB1 
receptor ligands and moclobemide in the FST 
and the TST
Mice given only acute single doses of oleamide (5 mg/kg), 
AM251 (0.25 mg/kg), or moclobemide (1.5 mg/kg) strug-
gled for the same duration of time as the vehicle-treated 
ones in both applied behavioural tests. Co-administration 
of AM251 and the antidepressant drug prolonged the mobil-
ity time of animals in the FST and in the TST. According 
to calculations performed by two-way ANOVA, signifi-
cant AM251–moclobemide interactions [F(1,28) = 8.19; 
p = 0.0122 and F(1,28) = 18.72; p = 0.0002] with sig-
nificant effects of AM251 [F(1,28) = 13.00; p = 0.0012 
and F(1,28) = 6.06; p = 0.0203] and significant effects 
of moclobemide [F(1,28) = 19.74; p = 0.0001 and 
F(1,28) = 11.82; p = 0.0019] were detected in the FST and 
Fig. 1  Effect of a combined intraperitoneal administration of oleam-
ide or AM251 and bupropion in a, c the FST and b, d the TST in 
mice. Oleamide (5  mg/kg) and AM251 (0.25  mg/kg) were injected 
30  min before behavioural tests, while bupropion (10  mg/kg) was 
given 60  min before testing. The values represent mean + SEM 
(n = 7–10 animals per group). Two-way ANOVA was used for statisti-
cal analysis. The Bonferroni’s post hoc test showed: ***p < 0.001 ver-
sus oleamide or AM251; ^^p < 0.01; ^^^p < 0.001 versus bupropion
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the TST, respectively. Though Bonferroni’s post hoc test 
showed that mice receiving concurrent administration of 
oleamide and moclobemide struggled for a longer time than 
moclobemide-treated animals or oleamide-treated animals 
in the FST or the TST, respectively, a significant oleam-
ide–moclobemide interaction was not detected by two-way 
ANOVA. The statistical data were obtained as follows: 
(1) F(1,36) = 1.07; p = 0.3076 for oleamide–moclobemide 
interplay in the FST, and (2) F(1,36) = 2.73; p = 0.1070 for 
oleamide–moclobemide interplay in the TST. The outcomes 
from the behavioural tests are presented in Fig. 3.
Effects of a combined administration of the  CB2 
receptor ligands and moclobemide in the FST 
and the TST
The anti-immobility effect of a joint administration of per 
se sub-active doses of  CB2 receptor ligands (i.e. 0.25 mg/kg 
of JWH133 or AM630) with moclobemide (1.5 mg/kg) was 
not significantly stronger than the monotherapy. Though, 
as shown in Fig. 4, mice given JWH133 and moclobemide 
struggled a little bit longer in the FST than their control 
counterparts, the observed differences in behaviour were 
not prominent enough to be detected by two-way ANOVA 
as an indicator of a significant drug–drug interplay. Con-
sequently, the statistical analyses demonstrated the fol-
lowing results: (1) a non-significant JWH133–moclobe-
mide interaction in the FST: F(1,28) = 2.45; p = 0.1288, 
(2) non-significant JWH133–moclobemide interaction in 
the TST: F(1,28) = 0.84; p = 0.3667, (3) non-significant 
AM630–moclobemide interaction in the FST: F(1,28) = 0.22; 
p = 0.6425, and (4) non-significant AM630–moclobemide 
interaction in the TST: F(1,28) = 2.69; p = 0.1125.
Effects of a combined administration of the CB 
receptor ligands and bupropion or moclobemide 
on the spontaneous locomotor activity in mice
None of the tested agents, i.e. oleamide (5 mg/kg), AM251 
(0.25 mg/kg), JWH133 (0.25 mg/kg), AM630 (0.25 mg/
kg), bupropion (10 mg/kg), or moclobemide (0.15 mg/kg), 
given alone or in respective combinations influenced the 
Fig. 2  Effect of a combined intraperitoneal administration of 
JWH133 or AM630 and bupropion in a, c the FST and b, d the 
TST in mice. JWH133 (0.25 mg/kg) and AM630 (0.25 mg/kg) were 
injected 30 min before behavioural tests, while bupropion (10 mg/kg) 
was given 60  min before testing. The values represent mean + SEM 
(n = 7–8 animals per group). Two-way ANOVA was used for sta-
tistical analysis. The Bonferroni’s post hoc test showed: *p < 0.05; 
**p < 0.01; ***p < 0.001, versus JWH133 or AM630; ^^p < 0.01; 
^^^p < 0.001 versus bupropion
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spontaneous locomotor activity of the tested mice. (Data 
are presented in Table 1.) Consequently, two-way ANOVA 
demonstrated: (1) a non-significant oleamide–bupropion 
interaction: F(1,27) = 2.02; p = 0.1665, (2) non-signifi-
cant oleamide–moclobemide interaction: F(1,28) = 0.00; 
p = 0.9607, (3) non-significant AM251–bupropion inter-
action: F(1,28) = 0.61; p = 0.4396, (4) non-significant 
AM251–moclobemide interaction: F(1,28) = 0.51; 
p = 0.4816; (5) non-significant JWH133–bupropion inter-
action: F(1,26) = 0.11; p = 0.7431, (6) non-significant 
JWH133–moclobemide interaction: F(1,28) = 2.89; 
p = 0.0999, (7) non-significant AM630–bupropion inter-
action: F(1,26) = 1.24; p = 0.2754, and (8) non-signifi-
cant AM630–moclobemide interaction: F(1,28) = 1.16; 
p = 0.2904. 
Pharmacokinetic studies
Analysing the results of the pharmacokinetic studies, we 
took into consideration only these drug combinations that 
were effective in the behavioural tests. Thus, we found 
out that despite positive interaction in the FST and in the 
TST, neither oleamide (5 mg/kg) nor AM251 (0.25 mg/
kg) or AM630 (0.25 mg/kg) influenced the brain levels 
of bupropion (10 mg/kg) and/or moclobemide (1.5 mg/
kg). The following statistical data were obtained after 
applying t test: (1) t(18) = 0.5480, p = 0.5905 for oleam-
ide–bupropion combination, (2) t(14) = 0.1109, p = 0.9133 
for AM251–bupropion combination, (3) t(14) = 0.5416, 
p = 0.5966 for AM630–bupropion combination, and (4) 
t(10) = 1.842, p = 0.0953 for AM251–moclobemide combi-
nation. The outcomes are summarized in Table 2.
Discussion
The outcomes of our study for the first time demonstrated 
that CB receptor ligands are able to potentiate the antide-
pressant activity of bupropion and moclobemide in the 
recognized behavioural tests in albino Swiss mice. The 
endocannabinoid system attracted attention of scientists 
as a promising target for the antidepressant therapy a long 
Fig. 3  Effect of a combined intraperitoneal administration of oleam-
ide or AM251 and moclobemide in a, c the FST and b, d the TST 
in mice. Oleamide (5 mg/kg) and AM251 (0.25 mg/kg) were injected 
30  min before behavioural tests, while moclobemide (1.5  mg/kg) 
was given 60  min before testing. The values represent mean + SEM 
(n = 8–10 animals per group). Two-way ANOVA was used for sta-
tistical analysis. The Bonferroni’s post hoc test showed: **p < 0.01; 
***p < 0.001 versus oleamide or AM251; ^^p < 0.01; ^^^p < 0.001 
versus moclobemide
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time ago. It turned out that both  CB1 and  CB2 receptors are 
localized peripherally and centrally, including these parts 
of the brain that are involved in emotion-related responses, 
such as anxiety, low mood, or stress (i.e. the hippocampus, 
amygdala, prefrontal cortex) [14, 15]. In fact, Smaga et al. 
[16] demonstrated that rats with experimentally induced 
childhood- or adult-like depression (i.e. the Wistar Kyoto 
or olfactory bulbectomized animals, respectively) presented 
diverse alterations in the endocannabinoid system, which 
included down-regulation of CB receptors, disturbances in 
the brain levels of anandamide and 2-arachidonoylglycerol, 
and changed expression of enzymes implicated in synthesis 
or metabolism of endocannabinoids (i.e. N-acyl phosphati-
dylethanolamine-specific phospholipase d, monoacylglyc-
erol lipase, fatty acid amide hydrolase, diacylglycerol lipase 
α). Outcomes from clinical and post-mortem studies gener-
ally confirmed the pre-clinical ones, since abnormal levels 
of endocannabinoids were detected in serum of untreated 
female patients with major depression [17], whereas 
increased concentrations of endocannabinoids were found 
in the prefrontal cortex of both alcoholic [18] and depressed 
suicide victims [19]. Monteleone et al. [20] showed that 
polymorphism in the  CB1 receptor gene may be associated 
with a higher susceptibility to the development of depres-
sion in humans, whereas Onaivi and colleagues [21] found 
out that Japanese depressed and alcoholic patients presented 
polymorphism in cannabinoid  CB2 receptors. Additionally, 
Minocci et al. [22] demonstrated a significant association 
between polymorphism in the  CB2 receptor gene and occur-
rence of bipolar disorders.
Despite their opposite functional activity, agonists and 
inverse agonists/antagonists of CB receptors, including the 
ones used in our study, can exert the same responses in ani-
mal behavioural tests measuring an antidepressant-like or 
anxiolytic-like potential. Kruk-Słomka and colleagues [10] 
demonstrated that both  CB2 receptor agonist—JWH133 (0.5 
and 1 mg/kg) and  CB2 receptor inverse agonist/antagonist—
AM630 (0.5 mg/kg) when given at an acute dose induced 
anti-immobility effects in the FST in Swiss mice. Similar 
activity also produced the  CB1 receptor agonist—oleamide 
(10 and 20 mg/kg) [10] and inverse agonist/antagonist—
AM251 administered at the single dose of (0.5 or 0.3 mg/kg) 
in NMRI mice [23]. Interestingly, the responses induced by 
oleamide and JWH133 in the FST were attenuated/reversed 
Fig. 4  Effect of a combined intraperitoneal administration of 
JWH133 or AM630 and moclobemide in a, c the FST and b, d the 
TST in mice. JWH133 (0.25  mg/kg) and AM630 (0.25  mg/kg) 
were injected 30  min before behavioural tests, while moclobemide 
(1.5  mg/kg) was given 60  min before testing. The values repre-
sent mean + SEM (n = 8 animals per group). Two-way ANOVA was 
used for statistical analysis. The Bonferroni’s post hoc test showed: 
**p < 0.01 versus JWH133; ^^p < 0.01 versus moclobemide
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by per se ineffective doses of AM251 (0.25 mg/kg) and 
AM630 (2 mg/kg) [10].
In the present study, we showed that oleamide (5 mg/kg), 
AM251 (0.25 mg/kg), and AM630 (0.25 mg/kg) augmented 
the antidepressant activity of bupropion (10 mg/kg) in the 
FST and the TST, whereas JWH133 (0.25 mg/kg) did not 
have such a potential. Surprisingly, antidepressant effects of 
moclobemide (1.5 mg/kg) were considerably enhanced in 
both behavioural tests only by AM251 (0.25 mg/kg). Neither 
oleamide (0.5 mg/kg) nor JWH133 (0.25 mg/kg) or AM630 
(0.25 mg/kg) increased activity of moclobemide sufficiently 
enough to be recognized as a significant interaction by two-
way ANOVA. Since the same observations were made in 
two world widely used behavioural tests designed for meas-
urement of the antidepressant-like activity of substances 
belonging to diverse chemical classes, our results should be 
considered as reliable. Moreover, we would like to empha-
size that the outcomes were not confounded by hyper- or 
hypolocomotion of animals. The distance travelled by mice 
from all tested groups was comparable to the one covered 
by the vehicle-treated animals. Though altered motility of 
rodents can be expected after administration of cannabinoids 
[24, 25], our outcomes were in line with results published by 
Kruk-Słomka and colleagues [10].
It is quite interesting that the  CB1 receptor ligands acting 
oppositely, i.e. oleamide and AM251, influenced the activ-
ity of bupropion in the same manner. However, we should 
admit that such a bidirectional potentiation of the antide-
pressant action by cannabinoids had been observed before 
in our laboratory. The results of our previous studies dem-
onstrated that oleamide and AM251 when administered at 
the sub-threshold concentrations in albino Swiss mice can 
potentiate the antidepressant activity of imipramine (15 mg/
kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) 
[6]. They also enhanced the antidepressant-like properties 
of biometals (i.e. magnesium, 10 mg/kg and zinc, 5 mg/kg) 
inhibiting the glutamatergic neurotransmission [12]. Addi-
tionally, Kruk-Słomka et al. [10] reported that all of the CB 
receptor ligands used in the present experiments augmented 
the anti-immobility effects of anticholinergic scopolamine 
(0.3 mg/kg) in the murine FST. Apart from the antidepres-
sant-like effects, endo- and exocannabinoids are also able 
to produce the depressogenic (as well as anxiogenic and 
anxiolytic) ones in pre-clinical studies [26]. A similar trend 
can be observed in cannabis users—some of them confirm 
beneficial effects of cannabis in the depressive disorders 
Table 1  Effect of a combined intraperitoneal administration of (A) 
oleamide, (B) AM251, (C) JWH133, or (D) AM630 and bupropion or 
moclobemide on the spontaneous locomotor activity of mice
Oleamide (5  mg/kg), AM251 (0.25  mg/kg), JWH133 (0.25  mg/kg), 
and AM630 (0.25 mg/kg) were given 30 min before the experiment, 
whereas bupropion (10  mg/kg) and moclobemide (1.5  mg/kg) were 
injected 60  min before testing. The values represent mean ± SEM 
(two-way ANOVA followed by Bonferroni’s post hoc test)
Treatment (n = number of mice per 
group)
Travelled distance (cm)
(A) Vehicle + vehicle (n = 8) 412.1 ± 86.02
Oleamide + vehicle (n = 8) 470.1 ± 64.35
Bupropion + vehicle (n = 7) 683.3 ± 40.25
Bupropion + oleamide (n = 8) 511.8 ± 107.27
Vehicle + vehicle (n = 8) 662.6 ± 42.78
Oleamide + vehicle (n = 8) 511.5 ± 83.66
Moclobemide + vehicle (n = 8) 715.3 ± 55.72
Moclobemide + oleamide (n = 8) 552.3 ± 212.71
(B) Vehicle + vehicle (n = 8) 629.0 ± 82.22
AM251 + vehicle (n = 8) 647.6 ± 47.97
Bupropion + vehicle (n = 8) 833.8 ± 109.44
Bupropion + AM251 (n = 8) 708.6 ± 112.13
Moclobemide + vehicle (n = 8) 582.9 ± 74.32
Moclobemide + AM251 (n = 8) 703.1 ± 75.61
(C) Vehicle + vehicle (n = 8) 586.5 ± 49.79
JWH133 + vehicle (n = 8) 567.0 ± 53.30
Bupropion + vehicle (n = 8) 868.6 ± 86.04
Bupropion + JWH133 (n = 8) 800.6 ± 103.6
Moclobemide + vehicle (n = 8) 510.4 ± 65.53
Moclobemide + JWH133 (n = 8) 670.3 ± 38.75
(D) Vehicle + vehicle (n = 7) 550.3 ± 39.53
AM630 + vehicle (n = 7) 572.5 ± 48.02
Bupropion + vehicle (n = 8) 748.1 ± 61.70
Bupropion + AM630 (n = 8) 634.5 ± 80.94
Vehicle + vehicle (n = 7) 456.6 ± 72.04
AM630 + vehicle (n = 8) 544.9 ± 34.57
Moclobemide + vehicle (n = 8) 516.4 ± 75.66
Moclobemide + AM630 (n = 8) 518.1 ± 57.95
Table 2  Effects of CB receptor ligands on the brain levels of bupro-
pion and/or moclobemide in mice
Oleamide (5  mg/kg), AM251 (0.25  mg/kg), and AM630 (0.25  mg/
kg) were administered intraperitoneally 30  min before decapitation, 
whereas bupropion (10  mg/kg) and moclobemide (1.5  mg/kg) were 
injected intraperitoneally 60 min before decapitation. The values rep-
resent mean ± SEM (t test)





Bupropion + vehicle 1207 ± 130.8 10
Bupropion + oleamide 1317 ± 152.4 10
Bupropion + vehicle 1195 ± 204.0 8
Bupropion + AM251 1226 ± 189.8 8
Bupropion + vehicle 666.2 ± 88.78 8
Bupropion + AM630 597.6 ± 90.18 8
Moclobemide + vehicle 17.23 ± 1.289 5
Moclobemide + AM251 15.07 ± 0.4063 7
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[27], whereas the others experience a higher number of 
depressive symptoms [28]. Though scientists admit that the 
exact mechanism of this peculiar bidirectional activity of 
the  CB1 receptor ligands has not been discovered yet, they 
propose several explanations for this phenomena: (1) influ-
ence of testing conditions (i.e. animal strain, applied dose, 
environmental factors) that can induce either depressive- or 
antidepressant-like changes in the endocannabinoid system 
[29], (2) existence of the functional pools of CB receptors 
that are responsible for manifestation of the antidepressant 
or pro-depressive effects [26], (3) influence of other, non-
CB1 and non-CB2, cannabinoid receptors [23], or (4) specific 
localization of the  CB1 receptors in the opposing, i.e. inhibi-
tory (GABA-ergic) and excitatory (glutamatergic) terminals 
[30].
We assume that the observed oleamide–, AM251–, 
and AM630–bupropion interactions as well as the 
AM251–moclobemide interaction may be the result of 
enhanced monoaminergic neurotransmission in the brain. 
 CB1 receptors influence release of acetylcholine, dopamine, 
glutamate, γ-aminobutyric acid, noradrenaline, serotonin, 
and different hormones that are involved in the depression-
related behaviour.  CB2 receptors reduce secretion of pro-
inflammatory and enhance secretion of anti-inflammatory 
cytokines, whereas the immune responses are also impli-
cated in the pathogenesis of depression [24, 31, 32]. Addi-
tionally, cannabinoids are known to have an impact on the 
activity of adreno- and serotoninergic receptors [32–34] 
as well as on the functioning of SERT and NAT, i.e. the 
serotonin and noradrenaline transporters, respectively [32, 
35]. When given at high doses, they can inhibit the activ-
ity of monoamine oxidase [36]. We guess that the interplay 
between the cannabinoids applied in the present study and 
bupropion could have been particularly attributed to the 
intensified dopamine-related mechanisms. Bupropion is a 
dual inhibitor of dopamine and norepinephrine reuptake, and 
stimulation of CB receptors affects the secretion of dopa-
mine [37]. However, it should be noted that the observed 
results are not a consequence of the simple potentiation of 
dopamine activity in the brain. As described in the medical 
literature [38],  CB1 receptor ligands can either increase or 
decrease dopamine synthesis and dopamine release. Thus, 
the final effect of enhanced dopamine neurotransmission 
is most probably a result of a complex interplay between 
the endocannabinoid system and other neurotransmitters 
(such as GABA, glutamate, and others). It is difficult to say 
whether the AM630–bupropion interaction was also at least 
partially attributed to the  CB1 receptor-dependent mecha-
nisms or not. One the one side, several authors noted that 
AM630 can behave not only as a  CB2 receptor inverse ago-
nist/antagonist, but it can also act as a  CB1 receptor inverse 
agonist [39]; thus, it may exert similar effects to AM251. On 
the other hand, JWH133, which does not bind exclusively 
to  CB2 receptors but also has a low affinity to  CB1 receptors 
[40], did not affect the activity of bupropion. Actually, since 
AM630 and JWH133 act oppositely at  CB2 receptors, their 
different activity towards antidepressant effects of bupro-
pion could have been expected. Furthermore, a significant 
functional selectivity of the  CB2 receptor ligands found by 
several independent research teams [41–43] could have con-
tributed to the observed interplays in the behavioural stud-
ies. It was revealed that certain  CB2 receptor ligands may 
activate diverse downstream intracellular pathways or may 
activate the overlapping ones but with different potency.
As for the AM251–moclobemide synergism of action, the 
potentiation of the serotoninergic signalling may be respon-
sible. Monoamine oxidase inhibitors inhibit metabolism of 
serotonin and sympathomimetic amines, whereas AM251 
does not directly interact with adrenergic receptors but it 
interplays with the serotoninergic ones. According to the 
literature data [44], the  5HT1A receptors seem to be involved 
in the behavioural effects of AM251 treatment. Furthermore, 
Hill et al. [45] demonstrated that inhibition of monoamine 
oxidase (by tranycypromine) influenced cannabinoid recep-
tor binding and changed the levels of endocannabinoids. 
We think that other mechanisms can also contribute to the 
drug–drug interactions observed in our study, since AM251 
modulates the opioid signalling [23], whereas oleamide 
interplays with serotoninergic 5-HT2C and 5-HT7 receptors 
and affects the benzodiazepine receptor- and vanilloid recep-
tor-dependent transmissions [46]. All of these pathways are 
directly and/or indirectly involved in the mood control.
Pharmacokinetic analyses carried out in the present 
study allowed us to assess concentrations of bupropion and 
moclobemide in mice brains after their combined adminis-
tration with CB receptor ligands. This approach was aimed 
at determining drug–drug interactions involving changes 
in drug disposition. Augmentation of bupropion and/or 
moclobemide levels in the brain might have been an indica-
tion of the facilitated transport of these drugs through the 
blood–brain barrier [47] in the presence of alterations in 
the endocannabinoid signalling. However, though oleam-
ide, AM251, and AM630 intensified the anti-immobility 
responses recorded after administration of bupropion, none 
of them augmented the brain levels of this antidepressant 
drug. Similarly, potentiation of moclobemide effects in the 
FST and in the TST by AM630 was not accompanied by an 
increase of moclobemide concentration in the mice brain. 
Based on the above-mentioned results we believe that the 
drug–drug interactions detected in the behavioural tests were 
due to processes at the cellular level, so they are pharmaco-
dynamic in nature. Molecular studies are needed to explain 
the observed synergism of action.
The positive interaction between CB receptor ligands 
and bupropion and/or moclobemide found out in our study 
seems to be important from the clinical point of view, since 
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concurrent administration of antidepressants and agents 
affecting the endocannabinoid system (particularly via  CB1 
receptors) may improve the safety profile of the introduced 
treatment (due to dose reduction of either substances). Based 
on the literature data [9], we can also hypothesize that intro-
duction of such a drug–drug combination may accelerate the 
alleviation of depressive symptoms (due to the fast onset of 
cannabinoids biological activity). However, further tests are 
needed to verify this supposition.
Conclusion
The outcomes of the present study for the first time dem-
onstrated that both stimulation and inhibition of the  CB1 
receptor function may intensify the antidepressant effects 
of bupropion, whereas only inhibition of  CB1 receptors 
potentiates activity of moclobemide. Though the effects 
of bupropion were also enhanced by administration of the 
selective  CB2 receptor inverse agonist/antagonist AM630, 
the observed interaction could have been partially attrib-
uted to the  CB1 receptor-dependent mechanisms. The pre-
sent study provides further evidences that addition of agents 
influencing the endocannabinoid system to the conventional 
antidepressant therapy may be a good strategy for patients 
resistant to currently available drugs. However, we realize 
that more advanced experiments are necessary to confirm 
the validity of such an approach.
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